Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C., Yeo, J., Walmsley,Volume:
207
Language:
english
Journal:
Journal of Infectious Diseases
DOI:
10.1093/infdis/jis750
Date:
March, 2013
File:
PDF, 411 KB
english, 2013